ArticleMolecular therapy. Methods & clinical development2020
Development of Large-Scale Downstream Processing for Lentiviral Vectors.
Article in Molecular therapy. Methods & clinical development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- Fouling-Free Inertial Microfluidic Cell Clarification for Lentivirus Manufacturing.Biotechnology and bioengineering · 2026Article
- Challenges and Opportunities in Lentivirus Viral Vector Manufacturing for In Vivo Applications.Biomedicines · 2026Review
- Downstream Workflows for Intermediate Purification of Lentiviral Vectors Using Tangential Flow Filtration and AEX Membrane Chromatography.Engineering in life sciences · 2025Article
- Membrane adsorber design for lentiviral vector recovery.Molecular therapy. Methods & clinical development · 2025Article
- CRISPR-Cas technologies: Emerging tools from research to clinical application.Journal of microbiology (Seoul, Korea) · 2025Review
- Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses.Vaccines · 2025Review
- Development of Lentiviral Packaging Cells and Scale Up of Production to Meet the Growing Demand in Cell and Gene Therapy.Current gene therapy · 2025Review
- Investigating Ultrafiltration Membranes and Operation Modes for Improved Lentiviral Vector Processing.Engineering in life sciences · 2025Article
- Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors.Biomedicines · 2024Article
- Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line.Molecular therapy. Methods & clinical development · 2024Article
- Sucrose Treatment Enhances the Electrotransfer of DNA by Activating Phospholipase A2.Pharmaceutics · 2024Article
- Long-term stability of clinical-grade lentiviral vectors for cell therapy.Molecular therapy. Methods & clinical development · 2024Article
- Purification and Quality Control of Recombinant Proteins Expressed in Mammalian Cells: A Practical Review.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Article
- Process intensification for lentiviral vector manufacturing using tangential flow depth filtration.Molecular therapy. Methods & clinical development · 2023Article
- Article
- Implementation of Novel Affinity Ligand for Lentiviral Vector Purification.International journal of molecular sciences · 2023Article
- Size-selective downstream processing of virus particles and non-enveloped virus-like particles.Frontiers in bioengineering and biotechnology · 2023Review
- A feasibility study of different commercially available serum-free mediums to enhance lentivirus and adeno-associated virus production in HEK 293 suspension cells.Cytotechnology · 2022Article
- Lentiviral interferon: A novel method for gene therapy in bladder cancer.Molecular therapy oncolytics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interest in lentiviral vectors (LVs) has increased prominently for gene therapy applications, but few have reached the later stages of clinical trials. The main challenge has remained in scaling up the manufacturing process for the fragile vector to obtain high titers for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.